MEDIOCON INC – Lazabemide is a synthetic, selective and reversible monoamine oxidase-B (MAO-B) inhibitor that has been investigated for its effects on dopamine metabolism and neurodegenerative disorders. It has been studied particularly in Parkinson's disease and Alzheimer's disease research.
Lazabemide is a benzylamine-related small molecule that selectively inhibits monoamine oxidase-B. By inhibiting MAO-B, Lazabemide reduces the enzymatic metabolism of dopamine and other monoamines, making it an important compound in neurological and pharmacological research.
Product Name: Lazabemide
CAS Number: 98230-48-5
Molecular Formula: C₁₆H₂₀N₂O
Molecular Weight: Approximately 256.35 g/mol
Chemical Class: Selective MAO-B inhibitor
Synonyms: Lazabemide, Ro 19-6327, Ro-19-6327
PubChem CID: 3039
Lazabemide is a selective and reversible inhibitor of monoamine oxidase-B (MAO-B). MAO-B is an enzyme involved in the metabolism of dopamine and other monoamines in the central nervous system.
By inhibiting MAO-B activity, Lazabemide can reduce dopamine metabolism and increase dopaminergic activity in experimental systems. This mechanism has made Lazabemide useful as a research tool for investigating dopamine metabolism, neuroprotection and neurological disorders.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Lazabemide quality evaluation may include identity, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Lazabemide has been investigated in neurological research, particularly in relation to Parkinson's disease, Alzheimer's disease and dopamine metabolism. Clinical research has evaluated its MAO-B inhibition and potential effects on neurological symptoms.
Lazabemide should not be represented as an approved therapeutic product unless the applicable regulatory approval has been specifically established for the intended market.
Lazabemide is a defined synthetic small-molecule compound with molecular formula C₁₆H₂₀N₂O and molecular weight approximately 256.35 g/mol. It is identified by CAS 98230-48-5 and is also known as Ro 19-6327.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lazabemide API Manufacturer and Supplier in India (CAS 98230-48-5) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lazabemide API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance